Lv5
830 积分 2021-04-26 加入
New BTK Inhibitors May Combat Resistance in CLL
22天前
已完结
Anlotinib in progressive RAI-refractory differentiated thyroid cancer: long-term results and PET/CT prognostic markers
23天前
已完结
Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia
23天前
已完结
The tumour microenvironment in B cell lymphomas
2个月前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
2个月前
已完结
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
3个月前
已完结
ERK1/2 pro‐survival signalling is suppressed by pirtobrutinib in ibrutinib‐resistant MYD88‐mutated lymphoma cells
5个月前
已完结
A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease
5个月前
已完结
Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single‐centre, retrospective study
5个月前
已完结
ERK1/2 pro‐survival signalling is suppressed by pirtobrutinib in ibrutinib‐resistant MYD88‐mutated lymphoma cells
6个月前
已完结
皖公网安备34019202002308
